<DOC>
	<DOCNO>NCT02440438</DOCNO>
	<brief_summary>Clostridium difficile responsible 25 % report antibiotic associate diarrhea case virtually case pseudomembranous colitis ( PMC ) . The clinical spectrum C. difficile infection ( CDI ) vary severity asymptomatic carriage self-limited , mild , watery diarrhea , PMC , intestinal perforation , toxic megacolon , sepsis , fulminant colitis , death . In past decade , 027/NAP1/BI strain emerge world-wide implicated large outbreak increase severity , frequent recurrence , significant mortality . The host immune response influence severity CDI play crucial role CDI onset , progression , overall prognosis . Low serum concentration antibody direct toxin A &amp; B C. difficile associate high risk recurrence . However , conflict report .</brief_summary>
	<brief_title>Host Immune Response Clostridium Difficile Infection ( ICD )</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Hospitalized Suffering diarrhea relate C. difficile Confirmed diagnosis CDI Informed consent patient Affiliated social security regime Outpatient No confirm diagnosis CDI Decline participation Patient affiliate social security regime</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Clostridium difficile , recurrence , relapse , antibody , immune response , prognosis</keyword>
</DOC>